158 related articles for article (PubMed ID: 36222204)
1. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
2. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
3. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
4. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
5. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
6. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
7. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
8. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
9. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy.
Wang HW; Chen CY; Lai HC; Hu TH; Su WP; Lu SN; Hung CH; Chuang PH; Wang JH; Chen CH; Peng CY
Am J Cancer Res; 2023; 13(2):526-537. PubMed ID: 36895986
[TBL] [Abstract][Full Text] [Related]
10. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
11. Predicting the risk of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy: Validating the CAMD and AASL scores in China.
Wang S; Liu B; Fan X; Gao Y; Hong M; Xu Y
Saudi J Gastroenterol; 2022; 28(5):362-368. PubMed ID: 35170433
[TBL] [Abstract][Full Text] [Related]
12. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues.
Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O
Oncology; 2016; 90(4):199-208. PubMed ID: 26934505
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
14. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.
Lee HW; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2019 Sep; 39(9):1624-1630. PubMed ID: 31050379
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
[TBL] [Abstract][Full Text] [Related]
16. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
17. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
18. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
